Lv4
610 积分 2020-12-26 加入
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
1个月前
已完结
Linking tumour angiogenesis and tumour immunity
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
Navigating First-in-Human and Early-Phase Patient Studies: Study Designs, Risk Mitigation, and Population Selection Challenges
1个月前
已完结
Pancreatic cancer
3个月前
已完结
Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
4个月前
已完结
Choledocholithiasis Can Present with Marked Transaminases Elevation: Systematic Review and Meta-Analysis
5个月前
已完结
Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database
5个月前
已完结
The ovarian cancer drug market
5个月前
已关闭
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
7个月前
已完结
皖公网安备34019202002308
